NIH Names Dr. Philip E. Bourne First Associate Director for Data Science
News Dec 10, 2013
National Institutes of Health Director Francis S. Collins, M.D., Ph.D, has announced the selection of Philip E. Bourne, Ph.D., as the first permanent Associate Director for Data Science (ADDS).
"Phil will lead an NIH-wide priority initiative to take better advantage of the exponential growth of biomedical research datasets, which is an area of critical importance to biomedical research. The era of 'Big Data' has arrived, and it is vital that the NIH play a major role in coordinating access to and analysis of many different data types that make up this revolution in biological information," said Collins.
Dr. Bourne comes to the NIH from the University of California San Diego, where he is the Associate Vice Chancellor for Innovation and Industry Alliances of the Office of Research Affairs and a Professor in the Department of Pharmacology and the Skaggs School of Pharmacy and Pharmaceutical Sciences.
He also is the Associate Director of the Research Collaboratory for Structural Bioinformatics (RCSB) Protein Data Bank. Dr. Bourne was trained as a physical chemist and obtained his Ph.D. from The Flinders University in South Australia.
Dr. Bourne's professional interests focus on relevant biological and educational outcomes derived from computation and scholarly communication.
This work involves the use of algorithms, text mining, machine learning, metalanguages, biological databases, and visualization applied to problems in systems pharmacology, evolution, cell signaling, apoptosis, immunology, and scientific dissemination.
He has published over 300 papers and five books. One area to which he is extremely committed is to furthering the free dissemination of science through new models of publishing and better integration and subsequent dissemination of data and results.
Collins added, "I also must recognize and thank Dr. Eric Green, who served as the Acting ADDS since I announced the search to fill this new position. His willingness to take on this challenging role in its inception, and to get the ball rolling on the enormous tasks that accompany this high-priority initiative, is sincerely appreciated. Eric is certain to remain a tremendous source of knowledge and support as Phil continues the NIH's effort to manage 'Big Data'."
CRISPR Reveals New Targets for Promising Cancer DrugsNews
Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.READ MORE
New Algorithms Help Extract 3-D Biological Structure from Limited DataNews
CAMERA researchers capitalize on their Multi-Tiered Iterative Phasing approach to determine molecular structure of proteins and viruses from X-ray free electron laser data.READ MORE
Big-Data Analysis Points Toward New Drug Discovery MethodNews
A research team has developed a computational method to systematically probe massive amounts of open-access data to discover new ways to use drugs, including some that have already been approved for other uses.
Comments | 0 ADD COMMENT
EMBL Course: Introduction to Next Generation Sequencing
Apr 09 - Apr 12, 2018
EMBL Course: RNA Sequencing Library Preparation - How Low Can You Go?
Mar 19 - Mar 23, 2018
EMBL Course: Analysis and Integration of Transcriptome and Proteome Data
Mar 12 - Mar 16, 2018
EMBO | EMBL Symposium: Tissue Self-Organisation: Challenging the Systems
Mar 11 - Mar 14, 2018
EMBL Course: Bioinformatics Resources for Protein Biology
Mar 06 - Mar 08, 2018